TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER).
Travasol 2.75% in Dextrose 25% is a parenteral nutrition solution providing amino acids and carbohydrates. The amino acids serve as substrates for protein synthesis, while dextrose provides a source of calories and spares protein catabolism. It does not have a direct pharmacological target but supports metabolic functions.
| Metabolism | Amino acids are metabolized via transamination, deamination, and urea cycle pathways; dextrose is metabolized via glycolysis and the citric acid cycle. |
| Excretion | Renal: 100% as amino acids and dextrose metabolites; negligible biliary/fecal elimination. |
| Half-life | Not applicable as a single entity; amino acids have variable half-lives (minutes to hours), dextrose has a half-life of 1.5-2 hours in normoglycemic patients; clinical context: continuous infusion maintains steady state. |
| Protein binding | < 10% bound; primarily albumin for tryptophan and tyrosine; most amino acids unbound. |
| Volume of Distribution | 0.5-0.8 L/kg for amino acids (total body water); dextrose Vd ~ 0.2 L/kg; clinical meaning: rapid distribution into lean body mass. |
| Bioavailability | Intravenous: 100%; not administered via other routes. |
| Onset of Action | Intravenous: immediate (minutes) for caloric provision and nitrogen sparing; clinical effect (protein synthesis) within hours to days. |
| Duration of Action | Duration depends on infusion rate; continuous IV infusion provides sustained effect; post-infusion: metabolic effects persist for several hours. |
Intravenous administration only. Typical adult dose is 1 to 2 L per day, infused at a rate of 100 to 200 mL per hour, adjusted based on metabolic and fluid needs. Contains 2.75% amino acids and 25% dextrose.
| Dosage form | INJECTABLE |
| Renal impairment | In acute kidney injury or chronic kidney disease, dose reduction is typically not required for amino acid component; however, adjust fluid volume and dextrose content based on fluid and glucose tolerance. For GFR <30 mL/min/1.73 m², consider reducing total fluid volume to avoid overload and monitor electrolytes. In dialysis patients, administer during dialysis or adjust for fluid removal. |
| Liver impairment | In hepatic impairment, use with caution. For Child-Pugh class A, no adjustment; class B, consider reducing total protein intake (0.8-1.0 g/kg/day) and monitor ammonia; class C, avoid or use only if benefits outweigh risks, with dose adjustment based on encephalopathy status and close monitoring of amino acid profile. |
| Pediatric use | Weight-based dosing: Amino acid component 1-3 g/kg/day (0.1-0.3 g/kg/hour) depending on age and clinical status; dextrose component 5-20 mg/kg/min. Total fluid: For neonates, start at 60-80 mL/kg/day, increase as tolerated. For older children, 100-150 mL/kg/day. Adjust based on metabolic demands and clinical response. |
| Geriatric use |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER).
| Breastfeeding | Amino acids and dextrose are endogenous nutrients; no harm expected in breastfeeding. M/P ratio not applicable or known. |
| Teratogenic Risk | Travasol 2.75% in Dextrose 25% is not a drug but a nutrient solution. No fetal risks are expected from amino acids and dextrose at therapeutic doses. However, hyperglycemia from dextrose may cause fetal macrosomia and neonatal hypoglycemia if maternal glucose is poorly controlled. No specific teratogenicity in any trimester. |
■ FDA Black Box Warning
None specified by FDA for this specific formulation.
| Serious Effects |
["Hypersensitivity to any component","Severe hyperglycemia or hyperosmolar state","Uncorrected electrolyte abnormalities","Severe hepatic failure or encephalopathy","Severe renal impairment without appropriate adjustments","Inborn errors of amino acid metabolism (e.g., phenylketonuria)","Galactosemia (due to dextrose cross-contamination in some formulations)"]
| Precautions | ["Risk of infection from catheter-related bloodstream infections","Fluid and electrolyte imbalances","Hyperglycemia or hypoglycemia","Hepatic steatosis or cholestasis","Metabolic acidosis or alkalosis","Aluminum toxicity in neonates or renal impairment","Refeeding syndrome in severely malnourished patients","Monitor serum electrolytes, glucose, liver function, and triglycerides"] |
Loading safety data…
| Elderly patients often require lower fluid volumes due to reduced cardiac and renal reserve. Start at 500-1000 mL per day, infuse at 50-100 mL/hour. Monitor glucose and electrolytes closely, as dextrose load may cause hyperglycemia. Adjust based on renal function (eGFR) and comorbidities. |
| Fetal Monitoring |
| Monitor maternal blood glucose, electrolytes, and fluid balance during infusion. Fetal monitoring per standard obstetric care, particularly if maternal glucose is elevated. |
| Fertility Effects | No known effects on fertility from amino acids or dextrose at standard parenteral nutrition doses. |